{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1235.350",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2023-08-08T01:00:54.000-04:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "B.well Connected Health Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2023-08-08"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2023-08-08"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1235.350"
    }
  ],
  "version" : "20230808",
  "name" : "COVID19Vaccine_EventClinicalGrouping",
  "title" : "COVID19 Vaccine_Event Clinical Grouping",
  "status" : "active",
  "date" : "2023-08-08T01:00:54-04:00",
  "publisher" : "B.well Connected Health Steward",
  "description" : "b.well created value set by Sr. Clinical Business Analyst for the COVID19 Vaccine_Event Clinical Grouping.",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Data Element Scope: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Inclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Exclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.)",
  "compose" : {
    "include" : [
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349"
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:26d8b5d3-8ffd-44dd-93c0-45b4c7b20c14",
    "timestamp" : "2023-11-26T19:06:56-05:00",
    "total" : 74,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0001A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0002A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0003A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0004A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0011A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0012A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0013A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; third dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0031A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; single dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0034A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0041A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0042A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0051A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; first dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0052A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; second dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0053A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; third dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0054A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0064A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0071A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0072A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0073A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; third dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0074A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0081A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0082A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0083A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, third dose (6 months through 4 years)"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0091A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; first dose, when administered to individuals 6 through 11 years"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0092A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; second dose, when administered to individuals 6 through 11 years"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0093A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; third dose, when administered to individuals 6 through 11 years"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0094A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0111A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0112A",
        "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0113A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 25 mcg/0.25 ml dosage; third dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0124A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, tris-sucrose formulation, booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0144A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrnalnp, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage, booster dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "0154A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 10 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation, booster dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "207",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "208",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "210",
        "display" : "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "211",
        "display" : "SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "212",
        "display" : "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "217",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "218",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "219",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "221",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "227",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "228",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "229",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "230",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "2468235",
        "display" : "SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "2470234",
        "display" : "SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "2479835",
        "display" : "SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "300",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "301",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "302",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "502",
        "display" : "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "506",
        "display" : "SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "510",
        "display" : "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "511",
        "display" : "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "518",
        "display" : "SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "519",
        "display" : "SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20231102",
        "code" : "520",
        "display" : "SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91300",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91301",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91303",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "91304",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91304",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91305",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91306",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91307",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91308",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91309",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91311",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91312",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, trissucrose formulation, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91313",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, spike protein, bivalent, preservative free, 50 mcg/0.5 ml dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91314",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage, for intramuscular use"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "91315",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 10 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
      }
    ]
  }
}
